4,5-Thiazoledicarboxylicacid, 2-Methyl-, 4,5-Diethyl Ester

In cGMP manufacturing of non‑peptidic HIV‑1 protease inhibitor pharmacophores, diethyl 2‑methyl‑4,5‑thiazoledicarboxylate is consumed as a regiochemically defined precursor for introduction of the 2‑methylthiazole‑4‑carboxamide motif responsible for backbone‑binding affinity within the enzyme active site. The ester is first subjected to alkaline saponification in a 5000 L glass‑lined reactor charged with THF/water (4:1 v/v) and aqueous sodium hydroxide, maintaining a jacket temperature of 55 ± 2 °C; instantaneous pH excursions above 12.5 during caustic dosing are a documented root cause of irreversible thiazole ring‑opening, evidenced by a step‑loss in isolated yield to below 72%. This risk is mitigated by in‑line pH probes interlocked with a programmable metering pump. After neutralisation and extraction of neutral impurities with methyl tert‑butyl ether, the aqueous phase is acidified to pH 2.8 with hydrochloric acid to precipitate 2‑methyl‑4,5‑thiazoledicarboxylic acid, which is isolated on a pressure‑filter dryer and dried under ≤10 mbar at 40 °C to a moisture endpoint of ≤0.15%. For subsequent amide bond formation with a chiral aminolactam intermediate, the diacid is activated via EDC·HCl/HOBt in dimethylformamide; the activated ester is used at a molar ratio of 1.08–1.15 equivalents relative to the amine coupling partner. Every campaign batch complies with ICH Q7 Section 12 for critical intermediate control, ICH M7 for mutagenic impurity hazard assessment, and USP <467> for residual solvents. The resulting thiazole‑carboxamide fragment is integrated into a multi‑drug antiretroviral regimen, typically paired with a pharmacokinetic enhancer, and delivered as film‑coated bilayer tablets for oral administration.

What Enables High‑T_g Polyesters When Aliphatic Diols Are Used?

Incorporation of the heteroaromatic ring furnished by diethyl 2‑methyl‑4,5‑thiazoledicarboxylate into amorphous polyester backbones consistently shifts the glass transition temperature above 120 °C while retaining melt processability on conventional stretching lines. The monomer is introduced via a two‑stage melt polycondensation: in a first transesterification vessel, the diethyl ester is equilibrated with an excess of a cycloaliphatic diol—preferably 1,4‑cyclohexanedimethanol—in the presence of titanium tetrabutoxide catalyst at 220–235 °C under a slow nitrogen sweep to strip evolving ethanol. Once the ester interchange is complete, freshly saponified 2‑methyl‑4,5‑thiazoledicarboxylic acid is metered into the oligomer melt to achieve a total heterocyclic diacid content of 35–50 mol% of total dicarboxylic monomers. Operation above the 50% threshold causes a non‑linear increase in melt viscosity accompanied by a b* colour coordinate exceeding 8, rendering the resulting chips unacceptable for fibre‑grade downstream conversion. The viscous mass is transferred to a 28 m³ horizontal high‑vacuum finisher (Hitachi‑type twin‑shaft design) where polycondensation proceeds at 285–295 °C and an absolute pressure of 30–45 Pa for a precisely controlled residence time of 60–90 min. An on‑line viscometer triggers automatic pelletising once the intrinsic viscosity reaches 0.72–0.78 dL/g (measured in 60/40 phenol/tetrachloroethane at 30 °C). The resulting BOPET‑grade film meets IEC 60674‑3‑4 electrical insulation requirements and UL 94 VTM‑0 flammability classification; it is slit into rolls for flexible printed circuit dielectric layers and wound capacitor housings. The substance is listed on TSCA inventory and has completed REACH pre‑registration for this supply chain.

Converting diethyl 2‑methyl‑4,5‑thiazoledicarboxylate into 4‑aminocarbonyl‑2‑methylthiazole‑5‑carboxylic acid represents a tandem regioselective monodecarboxylation‑ammonolysis sequence that avoids the cyanide‑based routes previously common in succinate dehydrogenase inhibitor (SDHI) fungicide manufacture. The selective 5‑decarboxylation is executed in anhydrous dimethyl sulfoxide with 1.05 equivalents of lithium chloride under rigorous exclusion of water (H₂O < 500 ppm) at 160 °C, converting the diester to ethyl 2‑methylthiazole‑4‑carboxylate with minimal formation of the isomeric 5‑ester. Subsequent treatment with methanolic ammonia in a 316L stainless‑steel pressure‑rated vessel affords the amide intermediate. Across the entire sequence the overall molar yield stabilises around 55%, so that for every kilogram of final active ingredient the initial charge of the diester is maintained at 1.7–1.9 kg. The process is executed under Good Agricultural Chemical Practice with reference to FAO/WHO JMPR residue definitions, EPA 40 CFR Part 158 product chemistry data requirements, and OECD 307 aerobic soil transformation testing. In‑line FTIR monitoring of the carbonyl stretching region provides real‑time endpoint detection for the deprotection step, improving batch‑to‑batch consistency. The resulting amide‑containing active is formulated into a 250 g/L suspo‑emulsion or water‑dispersible granule, and it is registered for foliar application against QoI‑resistant strains of Zymoseptoria tritici and Puccinia spp. in cereal production systems.

Corrosion Inhibition of Yellow Metals in Chloride‑Contaminated Service Water

Hydrolysis of diethyl 2‑methyl‑4,5‑thiazoledicarboxylate with potassium hydroxide yields an equilibrium mixture of monopotassium and dipotassium salts of 2‑methyl‑4,5‑thiazoledicarboxylic acid, which acts as a mixed‑type corrosion inhibitor for copper, brass and phosphor bronze exposed to water‑glycol or emulsion‑based machining fluids containing up to 200 ppm chlorides. The concentrate is prepared in a 1000 L jacketed glass‑lined reactor by adding the diester to 48% KOH solution at a molar ratio of 1 : 1.05 and stirring at 60 °C for 2 h; the resultant transparent amber liquid is adjusted with deionised water to a final actives content of 4.0–6.5 wt% (as potassium salt) and exhibits a pH (1% dilution) of 9.0 ± 0.3. In the diluted working fluid the inhibitor concentration settles at 0.15–0.30%, sufficient to achieve a 1b rating on the ASTM D130‑19 copper strip tarnish test carried out at 100 °C for 3 h. Complementary corrosion protection is validated by ASTM D4627‑22 cast‑iron chip tests and DIN 51360‑2 foam/water‑hardness stability procedures. The formulated metalworking fluid is deployed in high‑speed turning and grinding of lead‑free brass fittings and cupronickel valve bodies, where it suppresses the selective dezincification that conventional benzotriazole‑based packages fail to control. A documented operational boundary exists: if the working solution pH drifts below 8.2 due to bacterial acidogenesis, the thiazole‑dicarboxylate film desorbs from the cuprous oxide sublayer within 4–6 h, causing immediate tarnish; thus, post‑dosing with a boric acid/alkanolamine buffer and daily refractometric inhibitor tracking are mandatory.

Latent Acceleration of DICY‑Cured Epoxies — Processing Window Expander or Gelation Risk?

Diethyl 2‑methyl‑4,5‑thiazoledicarboxylate, when paired with a substituted imidazole, functions as a latency‑preserving accelerator in dicyandiamide‑epoxy systems by lowering the onset curing exotherm from 160 °C to approximately 115 °C while confining the viscosity growth at 40 °C storage for 28 days to less than 2.5‑fold. The dual‑accelerator package is engineered at a mass ratio of 0.6–1.2 phr of the diester with 0.3 phr of 2‑phenylimidazole, pre‑dissolved in a monoglycidyl ether reactive diluent and incorporated into the base resin (DGEBA, EEW 188–192 g/eq) under high‑shear dispersion on a three‑roll mill with a hydraulic gap setting of 10 µm, achieving a grind fineness consistently below 12 µm. Formulations must be processed under vacuum to remove entrained air generated during the milling pass; otherwise micro‑voids act as nucleation points for premature crosslinking. The cured adhesive complies with IPC‑SM‑817 for structural bonding in electronic assemblies and meets IEC 61249‑2‑21 halogen‑free requirements when post‑cured above 130 °C. The resulting one‑component paste is applied by pneumatic jet dispensing onto IGBT power‑module substrates and carbon‑fibre prepreg tooling faces. However, the diester exhibits a sharp incompatibility boundary: in epoxy‑amine systems, the 4‑carboxylate group catalyses rapid epoxide homopolymerisation and generates a gel within 30 s even at 25 °C, restricting its viable use strictly to acid‑anhydride or latent DICY curing regimes. The pot life at 25 °C for the DICY‑containing formulation is 6–8 h, after which the dynamic viscosity exceeds the threshold for stencil printing.

Site‑selective functionalization of diethyl 2‑methyl‑4,5‑thiazoledicarboxylate permits convergent assembly of kinase inhibitor pharmacophores without recourse to extensive protecting‑group interconversions, particularly the 4‑(2‑methylthiazolyl)phenyl urea chemotype recurrent in agents targeting anaplastic lymphoma kinase and ROS1 rearrangements. The C4‑ethyl ester is reduced preferentially with 1.0 equivalent of lithium aluminium hydride at 0–5 °C in anhydrous THF, leaving the C5‑ester intact to yield ethyl 2‑methyl‑5‑(hydroxymethyl)thiazole‑4‑carboxylate. The tolerance for stoichiometric deviation is exceptionally narrow: an excess of reducing agent of merely ±3% triggers over‑reduction of the 5‑ethoxycarbonyl group, generating a diol that cannot be separated from the desired product by standard fractional crystallisation. This milestone reduction is carried out in 100–500 L glass‑lined reactors fitted with a reaction calorimeter (Mettler Toledo RC1e) to profile heat generation, as the violent hydrogen evolution poses a vessel over‑pressure risk above 50 °C. After aqueous quench and toluene extraction, the hydroxymethyl intermediate is oxidised with Dess‑Martin periodinane to the aldehyde and further elaborated via Wittig olefination and Suzuki coupling to obtain the target kinase inhibitor precursor. All batches serving as starting materials under ICH Q11 must satisfy impurity fate and purge studies, and residual palladium and titanium are validated against ICH Q3D oral permitted daily exposure limits. The final dosage form is a conventional immediate‑release capsule or tablet intended for patients with locally advanced or metastatic non‑small cell lung carcinoma harbouring gene fusions amenable to targeted therapy; the marketing authorisation dossier references the intermediate’s process validation data to justify the starting-material designation.